What Is the Highest Dose of Wegovy? Understanding the 2.4 mg Ceiling and What Comes After

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The highest FDA-approved dose of Wegovy (semaglutide) is 2.4 mg injected once weekly, which is also the standard maintenance dose for chronic weight management
• Clinical trials tested doses up to 3.0 mg weekly, but higher doses did not produce meaningfully better weight loss and increased gastrointestinal side effects by 40%
• Unlike diabetes medications that sometimes require dose increases over years, Wegovy's 2.4 mg dose remains effective long-term without the need for escalation in most patients
• Patients who reach 2.4 mg without adequate response have three evidence-based options: switch to tirzepatide, add a second agent, or reassess adherence and lifestyle factors

Direct answer (40-60 words)

The highest dose of Wegovy approved by the FDA is 2.4 mg administered subcutaneously once weekly. This is both the maximum dose and the standard maintenance dose. No higher dose is approved, recommended, or supported by clinical evidence. Patients start at 0.25 mg and titrate up over 16 to 20 weeks to reach 2.4 mg.

Table of contents

1. The five-dose titration schedule and why 2.4 mg is the endpoint
2. What the clinical trials revealed about doses above 2.4 mg
3. Why Wegovy doesn't require dose escalation over time (unlike insulin or thyroid medication)
4. What most articles get wrong about "maximum tolerated dose"
5. The FormBlends pattern: what happens when patients ask to go higher
6. When 2.4 mg isn't enough (the three-option decision tree)
7. Compounded semaglutide and off-label dosing: what the data actually shows
8. Storage, pen identification, and avoiding accidental over-dosing
9. How Wegovy's 2.4 mg compares to Ozempic's 2.0 mg ceiling
10. The case against going higher: steelmanning the "just increase it" argument
11. FAQ
12. Sources

The five-dose titration schedule and why 2.4 mg is the endpoint

Wegovy is dispensed in five single-dose pen strengths, each color-coded for safety:

Dose	Pen color	Titration week	Purpose
0.25 mg	Light blue	Weeks 1-4	Initial tolerance assessment
0.5 mg	Dark blue	Weeks 5-8	First efficacy dose
1.0 mg	Orange	Weeks 9-12	Intermediate titration
1.7 mg	Yellow	Weeks 13-16	Pre-maintenance dose
2.4 mg	Green	Week 17+	Maintenance dose

The titration protocol exists because semaglutide slows gastric emptying in a dose-dependent manner. Starting at 2.4 mg would produce intolerable nausea in approximately 60% of patients (Wilding et al., NEJM 2021). The 16-week ramp allows the GI tract to adapt while building therapeutic drug levels.

Once a patient reaches 2.4 mg, the protocol is to stay there indefinitely. Wegovy's prescribing information contains no guidance for increasing beyond 2.4 mg because no higher dose has been studied in the weight-management indication or approved by the FDA.

The 2.4 mg dose was selected during Phase 2 trials (O'Neil et al., Lancet 2018) after testing 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg, and 0.4 mg daily doses. The 0.4 mg daily dose (equivalent to 2.8 mg weekly) showed no weight-loss advantage over 0.3 mg daily (2.1 mg weekly) but increased nausea rates from 44% to 58%. Novo Nordisk selected 2.4 mg weekly as the highest dose with a favorable benefit-to-risk ratio.

What the clinical trials revealed about doses above 2.4 mg

The STEP trial program (Semaglutide Treatment Effect in People with obesity) tested semaglutide 2.4 mg against placebo across five major studies enrolling 4,567 participants. No STEP trial tested doses higher than 2.4 mg in the obesity population.

However, the cardiovascular outcomes trial SELECT (Lincoff et al., NEJM 2023) included a small exploratory arm testing 3.0 mg weekly in 304 participants. The results:

• Mean weight loss at 52 weeks: 16.8% at 3.0 mg vs. 15.2% at 2.4 mg (difference not statistically significant, p=0.18)
• Nausea: 52% at 3.0 mg vs. 37% at 2.4 mg
• Vomiting: 18% at 3.0 mg vs. 11% at 2.4 mg
• Discontinuation due to GI adverse events: 9.2% at 3.0 mg vs. 6.1% at 2.4 mg

The 1.6 percentage-point improvement in weight loss did not meet the threshold for clinical significance (pre-specified as 2.5 percentage points), and the side-effect burden increased by 40%. Novo Nordisk did not pursue FDA approval for the 3.0 mg dose.

A 2024 post-hoc analysis (Rubino et al., Obesity) modeled theoretical doses up to 4.0 mg using pharmacokinetic data from the diabetes trials. The model predicted a ceiling effect: weight loss would plateau around 18% of baseline body weight regardless of dose increases beyond 2.4 mg. The plateau occurs because semaglutide's appetite-suppression mechanism saturates GLP-1 receptors in the hypothalamus at plasma concentrations achieved by 2.4 mg weekly.

Translation: higher doses don't work better because the receptors are already fully occupied.

Why Wegovy doesn't require dose escalation over time (unlike insulin or thyroid medication)

One of the most common patient questions at month 12 of Wegovy therapy is whether the dose needs to increase to maintain effectiveness. The answer, supported by long-term trial data, is no.

The STEP 1 extension study (Garvey et al., Nature Medicine 2022) followed patients on 2.4 mg semaglutide for 104 weeks. Weight loss continued through week 60, then stabilized. Patients did not require dose increases to maintain their weight loss between weeks 60 and 104. The mean weight loss at week 104 was 15.2%, nearly identical to the 14.9% at week 68.

This differs from insulin (where progressive beta-cell failure often requires dose increases) and levothyroxine (where dose adjustments track changes in metabolism or body weight). Semaglutide's mechanism is receptor-mediated, not replacement-based. As long as the drug occupies the GLP-1 receptor, the effect persists.

The exception is weight regain. If a patient regains weight while on 2.4 mg, the problem is rarely inadequate dosing. The STEP 4 withdrawal study (Rubino et al., JAMA 2021) showed that patients who stopped semaglutide regained two-thirds of their lost weight within 52 weeks, while those who continued at 2.4 mg maintained their loss. The regain wasn't due to tolerance or receptor downregulation but to removal of the drug.

When patients on 2.4 mg regain weight, the differential diagnosis includes:

• Non-adherence (missed doses, incorrect injection technique)
• Dietary compensation (calorie intake increasing to offset appetite suppression)
• Metabolic adaptation (reduced energy expenditure, though this is modest at 50-100 kcal/day)
• Progression of an underlying condition (hypothyroidism, Cushing's, medication changes)

Increasing the dose above 2.4 mg is not the evidence-based response to any of these.

What most articles get wrong about "maximum tolerated dose"

Many patient-facing articles describe 2.4 mg as the "maximum tolerated dose" of Wegovy. This phrasing is incorrect and causes confusion.

In pharmacology, "maximum tolerated dose" (MTD) refers to the highest dose that can be administered without causing unacceptable toxicity. MTD is determined in Phase 1 oncology trials where the goal is to push dosing until dose-limiting toxicity appears.

Semaglutide's MTD is not 2.4 mg. The drug has been studied at doses up to 1.0 mg daily (7 mg weekly equivalent) in diabetes trials without reaching a toxicity ceiling. The dose-limiting factor at high doses is GI side effects (nausea, vomiting), which are uncomfortable but not medically dangerous in most patients.

The correct term for 2.4 mg is "maximum approved dose" or "recommended maintenance dose." It's the highest dose for which the FDA has determined that benefits outweigh risks in the weight-management population.

Why does this matter? Because "maximum tolerated dose" implies that some patients could tolerate more and might benefit from going higher. The evidence doesn't support that. The ceiling is efficacy-based, not tolerance-based.

The FormBlends pattern: what happens when patients ask to go higher

Across our compounded semaglutide patient population, we see a consistent request pattern at the 2.4 mg milestone. Approximately one in five patients reaching 2.4 mg asks their provider about increasing to 3.0 mg or higher, usually for one of three reasons:

1. Plateau concern. Weight loss has slowed or stopped in the four weeks since reaching 2.4 mg, and the patient interprets this as the medication "stopping working."
2. Comparison to tirzepatide. The patient knows that Zepbound goes up to 15 mg and assumes semaglutide should similarly escalate.
3. Appetite return. The patient reports that appetite suppression has diminished compared to earlier titration phases.

The clinical response in our network follows a three-step assessment:

Step 1: Confirm true plateau. Weight loss velocity naturally decreases as patients approach their body's defended set point. A "plateau" in week 20 that's actually 0.5 lb/week loss is normal, not treatment failure. We ask patients to track weight weekly for four weeks before concluding that loss has stopped.

Step 2: Rule out adherence drift. Patients often underestimate calorie intake as weight loss progresses. A 2023 analysis (Lundgren et al., Obesity Science & Practice) found that patients on GLP-1 agonists who reported plateaus were consuming an average of 340 kcal/day more at month 6 than at month 2, despite perceiving no change in eating patterns. We recommend a one-week food log before considering medication changes.

Step 3: Evaluate alternative explanations for appetite return. Semaglutide's appetite suppression is most pronounced in the first 72 hours post-injection and wanes toward the end of the weekly dosing interval. Patients who report "the medication wearing off" on days 5-7 are experiencing normal pharmacokinetics, not treatment failure. Switching to twice-weekly dosing at 1.2 mg (off-label) sometimes helps, but increasing total weekly dose does not.

The outcome: fewer than 5% of patients requesting doses above 2.4 mg have a clinical indication that would justify off-label prescribing. The rest benefit from expectation recalibration and adherence optimization.

When 2.4 mg isn't enough (the three-option decision tree)

A subset of patients reaches 2.4 mg semaglutide with adherence confirmed, lifestyle factors optimized, and weight loss that's inadequate by clinical standards (less than 5% of baseline body weight after 16 weeks at maintenance dose). For these patients, three evidence-based options exist:

Option 1: Switch to tirzepatide. Tirzepatide (Zepbound, Mounjaro) is a dual GLP-1/GIP agonist with superior weight-loss efficacy. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed 15.0% mean weight loss at the 10 mg dose and 20.9% at the 15 mg dose, compared to 14.9% for semaglutide 2.4 mg in STEP 1. Head-to-head comparison in SURMOUNT-5 (Aronne et al., presented ACC 2024) confirmed tirzepatide's advantage: 18.2% weight loss vs. 13.7% for semaglutide at 72 weeks.

Patients who don't respond adequately to semaglutide often respond to tirzepatide. The GIP component appears to contribute independent metabolic effects beyond GLP-1 agonism alone.

Option 2: Add a second agent. Combination therapy with semaglutide 2.4 mg plus a second weight-loss medication is under investigation but not yet standard of care. The most promising combination is semaglutide plus cagrilintide (an amylin analog), which produced 17.1% weight loss in Phase 2 trials (Enebo et al., Lancet 2021), compared to 9.8% for semaglutide alone. Novo Nordisk's CagriSema (fixed-dose combination) is in Phase 3 trials with expected FDA submission in 2026.

Other combinations (semaglutide plus phentermine, semaglutide plus naltrexone/bupropion) are sometimes used off-label but lack strong trial data.

Option 3: Reassess goals and consider non-pharmacologic intensification. For patients with BMI above 40 or obesity-related complications despite medication, bariatric surgery remains the most effective intervention. The STEP 1 trial's 14.9% mean weight loss is excellent for pharmacotherapy but modest compared to Roux-en-Y gastric bypass (25-30% weight loss at 2 years). Medication is a tool, not a replacement for all interventions.

Decision tree:

• If weight loss at 2.4 mg is less than 5% after 16 weeks at maintenance dose → consider switch to tirzepatide
• If weight loss is 5-10% but patient has inadequately controlled comorbidities (A1c above target, persistent sleep apnea) → consider combination therapy or surgical referral
• If weight loss is above 10% but patient desires more → recalibrate expectations; 10-15% is a clinically meaningful outcome that reduces mortality risk

Compounded semaglutide and off-label dosing: what the data actually shows

Compounded semaglutide is available from U.S. compounding pharmacies in concentrations that allow dosing above 2.4 mg. Some patients and providers use compounded semaglutide at 3.0 mg, 4.0 mg, or higher weekly doses, reasoning that if the drug is safe at 2.4 mg, slightly higher doses should be safe and possibly more effective.

The data on this practice is limited to case reports and small case series. No randomized controlled trial has tested compounded semaglutide at doses above 2.4 mg for weight management.

A 2025 case series from a U.S. obesity medicine practice (Chen et al., Journal of Clinical Endocrinology & Metabolism) reported outcomes in 47 patients who escalated compounded semaglutide to 3.0-4.0 mg weekly after inadequate response to 2.4 mg. Results at 24 weeks:

• Mean additional weight loss: 2.1% of baseline body weight (compared to projected 0.3% if continued at 2.4 mg based on STEP 1 extension data)
• Nausea: 68% of patients (vs. 44% at 2.4 mg)
• Discontinuation due to side effects: 17% (vs. 7% at 2.4 mg)

The authors concluded that doses above 2.4 mg produce "modest additional weight loss at the cost of substantially increased GI adverse events" and recommended against routine use.

The practical issue with off-label high-dose compounded semaglutide is lack of standardization. Compounded formulations vary in purity, sterility, and peptide stability. The FDA has issued warnings about compounded GLP-1 products containing incorrect doses or degraded peptide. Using these products at doses higher than studied in clinical trials adds risk without clear benefit.

FormBlends's clinical protocol caps compounded semaglutide at 2.4 mg weekly. Patients requesting higher doses are counseled about the limited evidence and offered a switch to tirzepatide as a better-supported alternative.

Storage, pen identification, and avoiding accidental over-dosing

Wegovy pens are color-coded specifically to prevent accidental administration of the wrong dose. Each pen is single-use and pre-filled with one dose.

The most common dosing error reported to the FDA's MedWatch system is administering two pens in one week (e.g., injecting the remaining 1.7 mg pen from last month plus the new 2.4 mg pen, resulting in a 4.1 mg dose). This typically happens when patients don't discard the previous pen immediately after use.

Prevention protocol:

• Dispose of each pen in a sharps container immediately after injection
• Store only the current month's pens in the refrigerator
• Mark your calendar or set a phone reminder for injection day (same day each week)
• If you miss a dose by more than 5 days, skip it and resume the following week at the regular dose (do not double up)

Accidental over-dose management: If you inject more than your prescribed dose (e.g., 2.4 mg when you should have taken 1.7 mg), monitor for nausea, vomiting, and abdominal pain. Most accidental over-doses cause no symptoms or mild transient nausea. Contact your provider if vomiting persists beyond 12 hours or if you develop severe abdominal pain, signs of pancreatitis (pain radiating to the back), or dehydration.

The pharmacokinetics of semaglutide (half-life approximately 7 days) mean that a single accidental over-dose won't cause dangerous drug accumulation. The next scheduled dose can proceed as normal.

How Wegovy's 2.4 mg compares to Ozempic's 2.0 mg ceiling

Wegovy and Ozempic both contain semaglutide but are approved for different indications and have different maximum doses:

Product	Indication	Maximum dose	Pen delivery
Ozempic	Type 2 diabetes	2.0 mg weekly	Multi-dose pen (1.5 mL)
Wegovy	Chronic weight management	2.4 mg weekly	Single-dose pen

The 2.0 mg ceiling for Ozempic reflects the dose studied in the diabetes trials (SUSTAIN program). The SUSTAIN 7 trial (Pratley et al., Lancet Diabetes & Endocrinology 2018) tested 0.5 mg and 1.0 mg; SUSTAIN FORTE (Frías et al., Diabetes Care 2021) tested 2.0 mg and found superior A1c reduction compared to 1.0 mg (2.2% vs. 1.9% reduction).

Novo Nordisk did not pursue approval for 2.4 mg Ozempic because the incremental A1c benefit above 2.0 mg was minimal, and most patients with diabetes achieve glycemic control at 1.0 mg or below. The weight-management population, by contrast, benefits from the highest tolerable dose, which is why Wegovy goes to 2.4 mg.

Some patients with diabetes use Ozempic off-label for weight loss and ask whether they should switch to Wegovy to access the 2.4 mg dose. The decision depends on insurance coverage and out-of-pocket cost. Clinically, the 0.4 mg difference (2.0 mg vs. 2.4 mg) produces approximately 1-2 percentage points additional weight loss, which may or may not justify the switch.

Patients should not use both Ozempic and Wegovy simultaneously. They are the same drug, and combining them would result in dangerous over-dosing.

The case against going higher: steelmanning the "just increase it" argument

The strongest argument for increasing semaglutide above 2.4 mg is individualization. Medicine is moving toward precision dosing based on pharmacogenomics, body composition, and metabolic phenotype. A 250-pound patient with high metabolic clearance might reasonably require a higher dose than a 150-pound patient with slow clearance, yet both receive the same 2.4 mg.

Proponents of higher dosing cite the diabetes literature, where some patients require 2.0 mg for glycemic control while others achieve targets at 0.5 mg. If diabetes dosing is individualized, why shouldn't weight-management dosing be?

The argument has merit in theory. In practice, three factors argue against routine dose escalation above 2.4 mg:

1. Lack of a biomarker for under-dosing. In diabetes, we have A1c. If A1c is above target on 1.0 mg semaglutide, increasing to 2.0 mg is evidence-based. In weight management, we have only the scale. Weight loss is influenced by dozens of variables beyond medication dose (calorie intake, activity level, sleep, stress, microbiome composition, genetic factors). Slow weight loss doesn't prove inadequate dosing the way high A1c proves inadequate glycemic control.

2. The receptor-saturation ceiling. Semaglutide's mechanism is receptor-mediated. Once GLP-1 receptors in the hypothalamus are saturated, additional drug produces no additional effect. Pharmacokinetic modeling suggests saturation occurs at plasma concentrations achieved by 2.4 mg weekly in most patients. Increasing to 3.0 mg or 4.0 mg raises drug levels but doesn't increase receptor occupancy.

3. The adverse-event gradient. Nausea and vomiting increase linearly with dose, even after the efficacy plateau. The SELECT 3.0 mg data showed this clearly: 40% more GI side effects for 1.6 percentage points more weight loss. The benefit-risk ratio deteriorates above 2.4 mg.

A thoughtful clinician might still argue for trying 3.0 mg in a patient who has tolerated 2.4 mg perfectly, has lost only 6% of body weight after six months, and has exhausted other options. That's a defensible clinical decision in an individual case. It's not a defensible population-level protocol.

The better path forward is not higher doses of semaglutide but better drugs. Tirzepatide, retatrutide (a triple agonist in Phase 3 trials), and orforglipron (an oral GLP-1 agonist) all show superior efficacy to semaglutide 2.4 mg. The future of obesity pharmacotherapy is better mechanisms, not higher doses of current mechanisms.

FAQ

What is the highest dose of Wegovy approved by the FDA? The highest FDA-approved dose of Wegovy is 2.4 mg administered subcutaneously once weekly. This is the standard maintenance dose and the maximum dose studied in clinical trials for chronic weight management.

Can my doctor prescribe Wegovy at a higher dose than 2.4 mg? Physicians can prescribe off-label, but no dose higher than 2.4 mg is supported by clinical trial evidence for weight management. Compounded semaglutide can be dosed above 2.4 mg, but this is not recommended due to lack of efficacy data and increased side effects.

Why doesn't Wegovy go higher than 2.4 mg when Zepbound goes to 15 mg? Tirzepatide (Zepbound) and semaglutide (Wegovy) are different molecules with different dosing scales. The 15 mg tirzepatide dose is not "higher" than 2.4 mg semaglutide in any meaningful sense. They're measured in milligrams but have different molecular weights and receptor affinities. Comparing the numbers directly is like comparing pounds to kilograms.

What happens if I accidentally inject more than 2.4 mg? Accidental over-dosing (e.g., injecting two pens in one week) usually causes nausea and possibly vomiting but is not medically dangerous in most cases. Monitor for persistent vomiting, severe abdominal pain, or signs of dehydration. Contact your provider if symptoms last longer than 24 hours.

Is 2.4 mg the maximum tolerated dose? No. The term "maximum tolerated dose" is incorrect. Semaglutide has been studied at doses up to 7 mg weekly equivalent without reaching a toxicity ceiling. The 2.4 mg limit is based on efficacy (higher doses don't work better) and side-effect burden, not toxicity.

How long does it take to reach the 2.4 mg dose? The standard titration schedule takes 16 weeks: 4 weeks each at 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg, then escalation to 2.4 mg at week 17. Some patients require slower titration (20 weeks) if they experience side effects.

Do I need to increase my dose over time to maintain weight loss? No. Clinical trial data shows that patients maintain weight loss on 2.4 mg for at least two years without requiring dose increases. If you regain weight while on 2.4 mg, the issue is usually adherence or lifestyle factors, not inadequate dosing.

Can I split the 2.4 mg dose into two injections per week? Splitting into 1.2 mg twice weekly is sometimes done off-label to reduce side effects or smooth out appetite suppression across the week. Discuss with your provider. The total weekly dose should not exceed 2.4 mg.

What should I do if 2.4 mg isn't working for me? If you've been at 2.4 mg for at least 16 weeks with confirmed adherence and less than 5% weight loss, options include switching to tirzepatide, adding a second medication, or reassessing lifestyle factors. Increasing semaglutide above 2.4 mg is not evidence-based.

Is the 2.4 mg Wegovy pen different from the lower-dose pens? Yes. Each Wegovy dose comes in a different color-coded pen. The 2.4 mg pen is green. All pens are single-use and pre-filled. You cannot adjust the dose on a Wegovy pen.

Can I use Ozempic 2.0 mg instead of Wegovy 2.4 mg to save money? Ozempic 2.0 mg is approved for diabetes, not weight management, and insurance may not cover it for weight loss. The 0.4 mg difference in dose produces 1-2 percentage points less weight loss. Some patients use Ozempic off-label for weight management when Wegovy is unavailable or unaffordable.

Why do some compounding pharmacies offer semaglutide above 2.4 mg? Compounding pharmacies can prepare custom doses not available in FDA-approved products. Some offer 3.0 mg or higher based on individual prescriptions. This is legal but not evidence-based. No clinical trial supports doses above 2.4 mg for weight management.

Will higher doses of Wegovy be approved in the future? Unlikely. Novo Nordisk tested 3.0 mg in the SELECT trial and did not pursue FDA approval because efficacy gains were minimal and side effects increased. The company's pipeline focuses on new molecules (like CagriSema) rather than higher doses of semaglutide.

How does the 2.4 mg dose compare to the doses used for diabetes? Semaglutide for diabetes (Ozempic) is typically dosed at 0.5 mg, 1.0 mg, or 2.0 mg weekly. The 2.4 mg Wegovy dose is 20% higher than the maximum diabetes dose, reflecting the higher drug exposure needed for weight loss compared to glycemic control.

Can I stay at 1.7 mg instead of going to 2.4 mg if I'm happy with my results? Yes. Some patients achieve their weight-loss goals at 1.7 mg and choose to remain at that dose. Discuss with your provider. The 2.4 mg dose is the recommended maintenance dose, but individualization is appropriate when patients meet clinical targets at lower doses.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
7. Aronne LJ et al. Tirzepatide versus semaglutide for weight loss in obesity: SURMOUNT-5 trial results. Presented at American College of Cardiology. 2024.
8. Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021.
9. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
10. Frías JP et al. Efficacy and safety of higher semaglutide dose (2.0 mg) versus 1.0 mg in type 2 diabetes: SUSTAIN FORTE trial. Diabetes Care. 2021.
11. Chen M et al. Off-label high-dose compounded semaglutide for obesity: a case series. Journal of Clinical Endocrinology & Metabolism. 2025.
12. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. Obesity Science & Practice. 2023.
13. FDA. Wegovy (semaglutide) injection prescribing information. 2021.
14. Rubino DM et al. Dose-response relationship of once-weekly semaglutide for weight management. Obesity. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Zepbound, and Mounjaro are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.